On the other hand, patients presenting high-risk mutations that are prone to relapse (Philadelphia chromosome (Ph)-positive or Ph-like ALL with ABL-class fusion) need more intensified treatment or even the introduction of new therapies that are being tested in numerous trials. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.